Erasca, Inc.
ERASNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $4.63B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.11$24.28
- Volume (live)
- -
- Avg. volume (3M)
- 5.16M
Erasca (ERAS) Stock Price & Financial Analysis
Erasca Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $14.36 - $15.26 |
|---|---|
| 52-Week High | $24.28 |
| 52-Week Low | $2.11 |
| Open | $14.71 |
| Volume (last close) | 8.48M |
| Average Volume (3M) | 5.16M |
| 50-Day MA | $16.36 |
|---|---|
| 200-Day MA | $14.44 |
| 1-Year Change | +487.75% |
| Market Cap | 4.63B |
|---|---|
| Shares Outstanding | 311.34M |
| Price to Book (P/B) | 12.79 |
| EV/EBITDA | -31.77 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Erasca at a Glance
As of the Oct 15, 2026 close, Erasca (ERAS) has a market capitalization of $4.63B.
As of its latest reported balance sheet, it holds $42.54M in cash and securities against $44.71M of debt, a net debt position of $2.17M.
Erasca does not currently pay a dividend.
The share price is up 487.7% over the past year. At $14.87 (the Oct 15, 2026 close) it sits within its 52-week range of $2.10 to $24.28, above its 200-day moving average of $14.44.
Based on 7 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $24.14, 62.3% above the Oct 15, 2026 close.
Frequently Asked Questions About Erasca
What is the current stock price for ERAS?
As of the Oct 15, 2026 close, ERAS stock trades at $14.87. The 52-week range is $2.11–$24.28, with a day range of $14.36–$15.26.
What is the P/E ratio for ERAS?
The P/E ratio (Price-to-Earnings) for ERAS is shown in the Key Statistics section. This valuation metric helps compare Erasca, Inc. to industry peers.
Does ERAS pay dividends?
Erasca does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ERAS?
Based on ratings from 7 professional analysts over the last 90 days, the consensus for ERAS is Buy. The average 12-month price target is $24.14, a 62.3% upside from the Oct 15, 2026 close of $14.87.
What is the market cap of ERAS?
As of the Oct 15, 2026 close, Erasca's market capitalization is $4.63B, classifying it as a mid-cap company. Erasca operates in the Healthcare sector within the Biotechnology industry.